🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05825651
Active, not recruiting Observational

Long COVID and Its Associations With Health Outcomes in Older Adults

NCT05825651 · tracked via the Priya Life Science China tracker
Sponsor
Peking University
Phase
Observational
Started
2023-04-24
Last updated
2024-12-12

Condition(s) studied

Long COVIDCOVID-19 PandemicElderly InfectionVaccine ReactionLifestyle FactorsReinfection

Investigational drug(s) / intervention(s)

no interventions

no interventions: This is an observational study without any intervention.

Study summary

The Peking University Health Cohort in Anning, Yunnan (PKUHC-AN) is a prospective cohort study carried out in Anning, Yunnan. The primary aim of this study is to investigate the impact of COVID-19 on older adults' health, and to provide high-quality evidence of real world research for the optimization of prevention and control strategies of COVID-19 and other emerging infectious diseases. Data will be collected regarding health status, history of COVID-19 infections and vaccines, lifestyle and socioeconomic characteristics, as well as the short- and long-term health outcomes.

Eligibility

Sex
ALL
Min age
60 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * 1\. ≥60 years * 2\. Resided in Anning in the past half year and have no plan to move out in next 1 year * 3\. Older adults who are willing to participate in this study with informed consent Exclusion Criteria: * 1\. Unable to answer questions or communicate * 2\. Older adults who are not willing to participate in this study or without informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Anning medical community Kunming Yunan

More Peking University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05825651 on ClinicalTrials.gov ↗ ← All trials in China